首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid
【2h】

Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid

机译:膝关节黏液补充:单次注射与五次标准玻尿酸注射后稳定化透明质酸之间的成本-效果分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Given the wide difference in price per vial between various presentations of hyaluronic acid, this study seeks to compare the effectiveness and treatment cost of stabilized hyaluronic acid (NASHA) in a single injection with standard preparations of hyaluronic acid (HA) in five injections in osteoarthritis (OA) of the knee. Fifty-four patients with knee osteoarthritis (Kellgren–Lawrence Grade II and III) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score greater than 7, with a homogeneous distribution of age, sex, BMI, and duration of disease, were included in this study. Patients were randomized into two groups: Group I was treated with NASHA (Durolane®) and Group II with HA (Go-ON®). Patient’s evolution was followed up at the 1st, 2nd, 4th, 8th, 12th, and 26th week after treatment. A statistically significant improvement in WOMAC score was observed for patients treated with NASHA versus those who received HA at Week 26. In addition, the need for analgesia was significantly reduced at Week 26 in the NASHA-treated group. Finally, the economic analysis showed an increased cost of overall treatment with HA injections. Our data support the use of the NASHA class of products in the treatment of knee OA.
机译:鉴于各种玻尿酸形式之间的每瓶价格差异很大,本研究旨在比较五种注射液在骨关节炎中单次注射与标准制剂透明质酸(HA)的稳定透明质酸(NASHA)的疗效和治疗费用(OA)的膝盖。五十四名膝关节骨性关节炎(Kellgren–Lawrence II级和III级)以及西安大略省和麦克马斯特大学关节炎指数(WOMAC)的疼痛评分均大于7,年龄,性别,BMI和病程均一,被纳入这项研究。将患者随机分为两组:第一组接受NASHA(Durolane ®)治疗,第二组接受HA(Go-ON ®)治疗。在治疗后的第1、2、4、8、12和26周对患者的病情进行随访。与在第26周接受HA治疗的患者相比,接受NASHA治疗的患者观察到WOMAC评分有统计学上的显着改善。此外,在接受NASHA治疗的患者中,第26周镇痛的需求显着降低。最后,经济分析显示,注射HA的整体治疗费用增加。我们的数据支持将NASHA类产品用于膝骨关节炎的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号